Ampio, Endo deal

Ampio's Vyrix Pharmaceutical Inc. subsidiary granted Endo's Paladin Labs Inc. subsidiary exclusive rights to market Zertane in Canada, South Africa, Sub-Saharan Africa and Latin America. Vyrix will receive an undisclosed upfront payment and is eligible for milestones and double-digit royalties. Zertane is under review in Australia to treat premature ejaculation (PD). Paladin plans to submit a regulatory application in Canada this year for the oral fast-dissolving tablet formulation of tramadol. The companies decline to disclose details. ...